ATE333465T1 - Methoden und mittel zur hemmung der cdk4- aktivität - Google Patents

Methoden und mittel zur hemmung der cdk4- aktivität

Info

Publication number
ATE333465T1
ATE333465T1 AT97920857T AT97920857T ATE333465T1 AT E333465 T1 ATE333465 T1 AT E333465T1 AT 97920857 T AT97920857 T AT 97920857T AT 97920857 T AT97920857 T AT 97920857T AT E333465 T1 ATE333465 T1 AT E333465T1
Authority
AT
Austria
Prior art keywords
cdk4
activity
methods
sup
cdk4 activity
Prior art date
Application number
AT97920857T
Other languages
German (de)
English (en)
Inventor
Kathryn L Ball
David P Lane
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609521.1A external-priority patent/GB9609521D0/en
Priority claimed from GBGB9621314.5A external-priority patent/GB9621314D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE333465T1 publication Critical patent/ATE333465T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97920857T 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4- aktivität ATE333465T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609521.1A GB9609521D0 (en) 1996-05-08 1996-05-08 Substances and their therapeutic use
GBGB9621314.5A GB9621314D0 (en) 1996-10-09 1996-10-09 Substances and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE333465T1 true ATE333465T1 (de) 2006-08-15

Family

ID=26309279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97920857T ATE333465T1 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4- aktivität

Country Status (7)

Country Link
US (3) US6962792B1 (Direct)
EP (1) EP0898580B9 (Direct)
JP (1) JP4205165B2 (Direct)
AT (1) ATE333465T1 (Direct)
AU (1) AU2707797A (Direct)
DE (2) DE69736351T4 (Direct)
WO (1) WO1997042222A1 (Direct)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042222A1 (en) 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity
GB9727277D0 (en) * 1997-12-23 1998-02-25 Medical Res Council Assay
DE69907151D1 (de) * 1998-02-18 2003-05-28 Theryte Ltd Krebsbehandlung
BR9907965A (pt) * 1998-03-23 2000-12-12 Du Pont Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, polipetìdios, processo de alteração do nìvel de expressão de uma proteìna ciclina em uma célula hospedeira, método de obtenção de um fragmento de ácido nucleìco, produto e método de avaliação de pelo menos um composto quanto à sua capacidade de inibir a atividade de uma proteìna ciclina
EP1338652A3 (en) * 1998-03-23 2004-05-19 E.I.Du pont de nemours and company Plant cell cyclin genes
WO2000038733A1 (en) * 1998-12-24 2000-07-06 Ucb S.A. Peptidic product, process and composition
CA2367385A1 (en) * 1999-04-07 2000-10-12 E.I. Du Pont De Nemours And Company Cell cycle in plants
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
GB2369823B (en) * 1999-11-30 2003-06-04 Cyclacel Ltd Assays for cyclin-interacting compounds
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
US20050153894A1 (en) * 1999-11-30 2005-07-14 Cyclacel Limited p21 peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
WO2004015073A2 (en) * 2002-08-07 2004-02-19 Exelixis, Inc. MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
GB0229151D0 (en) 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
WO2005040207A1 (en) * 2003-10-20 2005-05-06 F. Hoffmann-La Roche Ag Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family
AU2004285745A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
JP2009500314A (ja) * 2005-06-29 2009-01-08 セント ジョージス エンタープライシス リミテッド 遺伝子調節
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
AU2019247554A1 (en) 2018-04-06 2020-11-26 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
SI3849537T1 (sl) 2018-09-10 2025-03-31 Mirati Therapeutics, Inc. Kombinirane terapije
CN118324906A (zh) * 2024-06-14 2024-07-12 上海交通大学医学院附属上海儿童医学中心 p21特异性修饰的抗体及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759164A1 (de) 1977-12-31 1979-07-12 Basf Ag Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung
US5229018A (en) 1986-02-24 1993-07-20 Forrest Gabriel T Completion and workover fluid for oil and gas wells comprising ground peanut hulls
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
ATE242806T1 (de) 1992-10-16 2003-06-15 Cold Spring Harbor Lab Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
GB9305448D0 (en) 1993-03-17 1993-05-05 British Tech Group Semiconductor structure and method of manufacturing same
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
WO1995031995A1 (en) 1994-05-24 1995-11-30 Baylor College Of Medicine Mimetics of senescent cell derived inhibitors of dna synthesis
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
AU6548396A (en) 1995-07-20 1997-02-18 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1997042222A1 (en) 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity

Also Published As

Publication number Publication date
DE69736351T4 (de) 2009-07-23
DE69736351D1 (de) 2006-08-31
US20040214765A1 (en) 2004-10-28
JP4205165B2 (ja) 2009-01-07
WO1997042222A1 (en) 1997-11-13
US20080249025A1 (en) 2008-10-09
AU2707797A (en) 1997-11-26
US6962792B1 (en) 2005-11-08
DE69736351T2 (de) 2007-07-12
EP0898580A1 (en) 1999-03-03
EP0898580B9 (en) 2009-08-12
JP2000513805A (ja) 2000-10-17
EP0898580B1 (en) 2006-07-19
EP0898580B3 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
ATE333465T1 (de) Methoden und mittel zur hemmung der cdk4- aktivität
Kulikov et al. Mdm2 facilitates the association of p53 with the proteasome
EP1322307A4 (en) METHOD FOR THE TREATMENT OF CELL PROLIFERATION TROUBLES AND VIRUS INFECTIONS
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
WO2003029418A3 (en) Proliferation and differentiation of stem cells using extracellular matrix and other molecules
EP2261667A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and their therapy of ovarian cancer
WO2003072599A3 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
EP1192247A4 (en) SPHINGOSINEKINASE
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
WO2004069200A3 (en) Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
IL149416A0 (en) Human enzymes of the metalloprotease family
EP1887082A3 (en) TADG-15: An extracellular serine protease overexpressed in carcinomas
AU7525398A (en) Inhibitors for urokinase receptor
Nikolaev et al. PARC: a potential target for cancer therapy
ATE362768T1 (de) Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität
WO2004043371A3 (en) Methods and compositions for modulating p53 transcription factor
WO2004096991A3 (en) Bcl2l12 polypeptide activators and inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0898580

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
UEP Publication of translation of european patent specification

Ref document number: 0898580

Country of ref document: EP